{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:10:35Z","timestamp":1784041835383,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis C virus (HCV) infection poses a serious global public health burden. Despite the recent development of effective treatments there is a large unmet need for a prophylactic vaccine. Further, antiviral resistance might compromise treatment efficiency in the future. HCV cell culture systems are typically based on Huh7 and derived hepatoma cell lines cultured in monolayers. However, efficient high cell density culture systems for high-yield HCV production and studies of antivirals are lacking. We established a system based on Huh7.5 cells cultured in a hollow fiber bioreactor in the presence or absence of bovine serum. Using an adapted chimeric genotype 5a virus, we achieved peak HCV infectivity and RNA titers of 7.6 log<jats:sub>10<\/jats:sub>FFU\/mL and 10.4 log<jats:sub>10<\/jats:sub>IU\/mL, respectively. Bioreactor derived HCV showed high genetic stability, as well as buoyant density, sensitivity to neutralizing antibodies AR3A and AR4A, and dependency on HCV co-receptors CD81 and SR-BI comparable to that of HCV produced in monolayer cell cultures. Using the bioreactor platform, treatment with the NS5A inhibitor daclatasvir resulted in HCV escape mediated by the NS5A resistance substitution Y93H. In conclusion, we established an efficient high cell density HCV culture system with implications for studies of antivirals and vaccine development.<\/jats:p>","DOI":"10.1038\/s41598-018-35010-5","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T18:08:37Z","timestamp":1543255717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals"],"prefix":"10.1038","volume":"8","author":[{"given":"Anne F.","family":"Pihl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna F.","family":"Offersgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick","family":"Prentoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-5751","authenticated-orcid":false,"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-2428","authenticated-orcid":false,"given":"Henrik","family":"Krarup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-0256","authenticated-orcid":false,"given":"Judith M.","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"35010_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1099\/jgv.0.000672","volume":"98","author":"P Simmonds","year":"2017","unstructured":"Simmonds, P. et al. ICTV Virus Taxonomy Profile: Flaviviridae. The Journal of General Virology 98, 2\u20133 (2017).","journal-title":"The Journal of General Virology"},{"key":"35010_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrmicro3046","volume":"11","author":"R Bartenschlager","year":"2013","unstructured":"Bartenschlager, R., Lohmann, V. & Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nature Reviews Microbiology 11, 482\u2013496 (2013).","journal-title":"Nature Reviews Microbiology"},{"key":"35010_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm.3248","volume":"19","author":"TKH Scheel","year":"2013","unstructured":"Scheel, T. K. H. & Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature medicine 19, 837\u2013849 (2013).","journal-title":"Nature medicine"},{"key":"35010_CR4","doi-asserted-by":"crossref","unstructured":"Gottwein, J. M. & Bukh, J. Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture Systems In Advances in Virus Research Vol. 71 (eds Karl Maramorosch, Aaron Shatkin, & Frederick Murphy) Ch. 2, 51\u2013133 (Academic Press, 2008).","DOI":"10.1016\/S0065-3527(08)00002-X"},{"key":"35010_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet 388, 1081\u20131088 (2016).","journal-title":"The Lancet"},{"key":"35010_CR6","doi-asserted-by":"publisher","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns, M. P. et al. Hepatitis C virus infection. Nature Reviews Disease Primers 3, 17006 (2017).","journal-title":"Nature Reviews Disease Primers"},{"key":"35010_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh, B., Grebely, J. & Dore, G. J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology & Hepatology 10, 553\u2013562 (2013).","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"35010_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology 2, 161\u2013176 (2017).","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"35010_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky, J.-M. et al. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology 69, 461\u2013511 (2018).","journal-title":"Journal of Hepatology"},{"key":"35010_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"J-M Pawlotsky","year":"2016","unstructured":"Pawlotsky, J.-M. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 151, 70\u201386 (2016).","journal-title":"Gastroenterology"},{"key":"35010_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 64, 486\u2013504 (2016).","journal-title":"Journal of Hepatology"},{"issue":"7","key":"35010_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41575-018-0018-5","volume":"15","author":"Massimo Colombo","year":"2018","unstructured":"Colombo, M. & Boccaccio, V. HCV therapy and risk of liver cancer recurrence: who to treat? Nature Reviews Gastroenterology & Hepatology 15, 392\u2013393 (2018).","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"35010_CR13","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jhep.2014.09.009","volume":"61","author":"TF Baumert","year":"2014","unstructured":"Baumert, T. F., Fauvelle, C., Chen, D. Y. & Lauer, G. M. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing. Journal of Hepatology 61, S34\u2013S44 (2014).","journal-title":"Journal of Hepatology"},{"key":"35010_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","volume":"248","author":"R Bartenschlager","year":"2018","unstructured":"Bartenschlager, R. et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research 248, 53\u201362 (2018).","journal-title":"Virus Research"},{"key":"35010_CR15","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","volume":"65","author":"J Bukh","year":"2016","unstructured":"Bukh, J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology 65, S2\u2013S21 (2016).","journal-title":"Journal of Hepatology"},{"key":"35010_CR16","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","volume":"76","author":"KJ Blight","year":"2002","unstructured":"Blight, K. J., McKeating, J. A. & Rice, C. M. Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication. Journal of Virology 76, 13001\u201313014 (2002).","journal-title":"Journal of Virology"},{"key":"35010_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach, B. D. et al. Complete Replication of Hepatitis C Virus in Cell Culture. Science 309, 623 (2005).","journal-title":"Science"},{"key":"35010_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature medicine 11, 791\u2013796 (2005).","journal-title":"Nature medicine"},{"key":"35010_CR19","doi-asserted-by":"publisher","first-page":"7758","DOI":"10.1128\/JVI.00039-15","volume":"89","author":"CK Mathiesen","year":"2015","unstructured":"Mathiesen, C. K. et al. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. Journal of Virology 89, 7758\u20137775 (2015).","journal-title":"Journal of Virology"},{"key":"35010_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.antiviral.2006.05.023","volume":"71","author":"G Andrei","year":"2006","unstructured":"Andrei, G. Three-dimensional culture models for human viral diseases and antiviral drug development. Antiviral Research 71, 96\u2013107 (2006).","journal-title":"Antiviral Research"},{"key":"35010_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpba.2017.07.023","volume":"147","author":"K Jaroch","year":"2018","unstructured":"Jaroch, K., Jaroch, A. & Bojko, B. Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. Journal of Pharmaceutical and Biomedical Analysis 147, 297\u2013312 (2018).","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"35010_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3851\/IMP1770","volume":"21","author":"JJ McSharry","year":"2011","unstructured":"McSharry, J. J. & Drusano, G. L. Antiviral Pharmacodynamics in Hollow Fibre Bioreactors. Antiviral Chemistry and Chemotherapy 21, 183\u2013192 (2011).","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"35010_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/biol.1998.0153","volume":"26","author":"V Grachev","year":"1998","unstructured":"Grachev, V., Magrath, D. & Griffiths, E. WHO Requirements for the Use of Animal Cells as in vitro Substrates for the Production of Biologicals (Requirements for Biological Substances No. 50). Biologicals 26, 175\u2013193 (1998).","journal-title":"Biologicals"},{"key":"35010_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.virol.2014.03.021","volume":"458","author":"CK Mathiesen","year":"2014","unstructured":"Mathiesen, C. K. et al. Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1\u20136. Virology 458, 190\u2013208 (2014).","journal-title":"Virology"},{"key":"35010_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature Medicine 14, 25\u201327 (2008).","journal-title":"Nature Medicine"},{"key":"35010_CR26","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1073\/pnas.1114927109","volume":"109","author":"E Giang","year":"2012","unstructured":"Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 109, 6205\u20136210 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"35010_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.05383-11","volume":"56","author":"AN Brown","year":"2012","unstructured":"Brown, A. N. et al. Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System. Antimicrobial Agents and Chemotherapy 56, 1170\u20131181 (2012).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"35010_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3851\/IMP1770","volume":"21","author":"JM James","year":"2011","unstructured":"James, J. M. & George, L. D. Antiviral Pharmacodynamics in Hollow Fibre Bioreactors. Antiviral Chemistry and Chemotherapy 21, 183\u2013192 (2011).","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"35010_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","volume":"154","author":"JM Gottwein","year":"2018","unstructured":"Gottwein, J. M. et al. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1\u20137 and Escape Variants. Gastroenterology 154, 1435\u20131448 (2018).","journal-title":"Gastroenterology"},{"key":"35010_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","volume":"151","author":"S Ramirez","year":"2016","unstructured":"Ramirez, S., Mikkelsen, L. S., Gottwein, J. M. & Bukh, J. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Gastroenterology 151, 973\u2013985.e972 (2016).","journal-title":"Gastroenterology"},{"key":"35010_CR31","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","volume":"154","author":"LV Pham","year":"2018","unstructured":"Pham, L. V. et al. HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology 154, 2194\u20132208 (2018).","journal-title":"Gastroenterology"},{"key":"35010_CR32","doi-asserted-by":"publisher","first-page":"12776","DOI":"10.1128\/JVI.00901-13","volume":"87","author":"SBN Serre","year":"2013","unstructured":"Serre, S. B. N., Krarup, H. B., Bukh, J. & Gottwein, J. M. Identification of Alpha Interferon-Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance. Journal of Virology 87, 12776\u201312793 (2013).","journal-title":"Journal of Virology"},{"key":"35010_CR33","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.02929-15","volume":"60","author":"SBN Serre","year":"2016","unstructured":"Serre, S. B. N. et al. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrobial Agents and Chemotherapy 60, 3563\u20133578 (2016).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"35010_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010).","journal-title":"Nature"},{"key":"35010_CR35","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","volume":"140","author":"TKH Scheel","year":"2011","unstructured":"Scheel, T. K. H., Gottwein, J. M., Mikkelsen, L. S., Jensen, T. B. & Bukh, J. Recombinant HCV Variants With NS5A From Genotypes 1\u20137 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-\u03b1. Gastroenterology 140, 1032\u20131042.e1036 (2011).","journal-title":"Gastroenterology"},{"key":"35010_CR36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00253-012-4451-z","volume":"96","author":"M Butler","year":"2012","unstructured":"Butler, M. & Meneses-Acosta, A. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Applied Microbiology & Biotechnology 96, 885\u2013894 (2012).","journal-title":"Applied Microbiology & Biotechnology"},{"key":"35010_CR37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/14760584.2015.1067144","volume":"14","author":"L Gallo","year":"2015","unstructured":"Gallo, L., Nikolay, A., Genzel, Y. & Reichl, U. Bioreactor concepts for cell culture-based viral vaccine production. Expert review of Vaccines 14, 1181\u20131195 (2015).","journal-title":"Expert review of Vaccines"},{"key":"35010_CR38","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","volume":"100","author":"F Tapia","year":"2016","unstructured":"Tapia, F., V\u00e1zquez-Ram\u00edrez, D., Genzel, Y. & Reichl, U. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production. Applied Microbiology and Biotechnology 100, 2121\u20132132 (2016).","journal-title":"Applied Microbiology and Biotechnology"},{"key":"35010_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin, S. A. & Plotkin, S. A. Correlates of Vaccine-Induced Immunity. Clinical Infectious Diseases 47, 401\u2013409 (2008).","journal-title":"Clinical Infectious Diseases"},{"key":"35010_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrmicro2668","volume":"9","author":"SA Plotkin","year":"2011","unstructured":"Plotkin, S. A. & Plotkin, S. L. The development of vaccines: how the past led to the future. Nature Reviews Microbiology 9, 889\u2013893 (2011).","journal-title":"Nature Reviews Microbiology"},{"key":"35010_CR41","doi-asserted-by":"crossref","unstructured":"Aunins, J. G. Viral Vaccine Production in Cell Culture In Encyclopedia of Cell Technology Vol. 2 (ed. Raymond E. Spier) 1183\u20131207 (John Wiley & Sons, Inc., 2000).","DOI":"10.1002\/0471250570.spi105"},{"key":"35010_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2013.05.007","volume":"145","author":"D Akazawa","year":"2013","unstructured":"Akazawa, D. et al. Neutralizing Antibodies Induced by Cell Culture\u2013Derived Hepatitis C Virus Protect Against Infection in Mice. Gastroenterology 145, 447\u2013455 (2013).","journal-title":"Gastroenterology"},{"key":"35010_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/gutjnl-2016-312208","volume":"67","author":"H Yokokawa","year":"2018","unstructured":"Yokokawa, H. et al. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model. Gut 67, 372\u2013379 (2018).","journal-title":"Gut"},{"key":"35010_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrgastro.2013.136","volume":"10","author":"JM Gottwein","year":"2013","unstructured":"Gottwein, J. M. & Bukh, J. Cell-culture-derived HCV\u2014a promising vaccine antigen. Nature Reviews Gastroenterology & Hepatology 10, 508\u2013509 (2013).","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"35010_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.virol.2006.03.038","volume":"351","author":"K Murakami","year":"2006","unstructured":"Murakami, K. et al. Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. Virology 351, 381\u2013392 (2006).","journal-title":"Virology"},{"key":"35010_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1743-422X-6-103","volume":"6","author":"B Sainz","year":"2009","unstructured":"Sainz, B., TenCate, V. & Uprichard, S. L. Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virology Journal 6, 103\u2013103 (2009).","journal-title":"Virology Journal"},{"key":"35010_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/microarrays4010064","volume":"4","author":"A Bachmann","year":"2015","unstructured":"Bachmann, A. et al. 3D Cultivation Techniques for Primary Human Hepatocytes. Microarrays 4, 64\u201383 (2015).","journal-title":"Microarrays"},{"key":"35010_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.virol.2011.12.021","volume":"425","author":"F Molina-Jimenez","year":"2012","unstructured":"Molina-Jimenez, F. et al. Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology 425, 31\u201339 (2012).","journal-title":"Virology"},{"key":"35010_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ejps.2017.10.027","volume":"111","author":"CP Pires de Mello","year":"2018","unstructured":"Pires de Mello, C. P. et al. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. European Journal of Pharmaceutical Sciences 111, 443\u2013449 (2018).","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"35010_CR50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/physiol.00036.2016","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval, K. et al. Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology 32, 266\u2013277 (2017).","journal-title":"Physiology"},{"key":"35010_CR51","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1087057117696795","volume":"22","author":"Y Fang","year":"2017","unstructured":"Fang, Y. & Eglen, R. M. Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS DISCOVERY: Advancing Life Sciences R&D 22, 456\u2013472 (2017).","journal-title":"SLAS DISCOVERY: Advancing Life Sciences R&D"},{"key":"35010_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1517\/17460441.2015.1032241","volume":"10","author":"C Lin","year":"2015","unstructured":"Lin, C., Ballinger, K. R. & Khetani, S. R. The application of engineered liver tissues for novel drug discovery. Expert Opinion on Drug Discovery 10, 519\u2013540 (2015).","journal-title":"Expert Opinion on Drug Discovery"},{"key":"35010_CR53","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1002\/jbm.a.35044","volume":"102","author":"Y Hao","year":"2013","unstructured":"Hao, Y. & Lin, C. C. Degradable thiol\u2010acrylate hydrogels as tunable matrices for three\u2010dimensional hepatic culture. Journal of Biomedical Materials Research Part A 102, 3813\u20133827 (2013).","journal-title":"Journal of Biomedical Materials Research Part A"},{"key":"35010_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/biores.2015.0024","volume":"4","author":"S Balakrishnan","year":"2015","unstructured":"Balakrishnan, S. et al. A Scalable Perfusion Culture System with Miniature Peristaltic Pumps for Live-Cell Imaging Assays with Provision for Microfabricated Scaffolds. Biores Open Access 4, 343\u2013357 (2015).","journal-title":"Biores Open Access"},{"key":"35010_CR55","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/jcb.25356","volume":"117","author":"J Bomo","year":"2015","unstructured":"Bomo, J. et al. Increasing 3D Matrix Rigidity Strengthens Proliferation and Spheroid Development of Human Liver Cells in a Constant Growth Factor Environment. Journal of Cellular Biochemistry 117, 708\u2013720 (2015).","journal-title":"Journal of Cellular Biochemistry"},{"key":"35010_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.actbio.2017.12.042","volume":"69","author":"PL Lewis","year":"2018","unstructured":"Lewis, P. L., Green, R. M. & Shah, R. N. 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. Acta Biomaterialia 69, 63\u201370 (2018).","journal-title":"Acta Biomaterialia"},{"key":"35010_CR57","doi-asserted-by":"publisher","first-page":"e0118123","DOI":"10.1371\/journal.pone.0118123","volume":"10","author":"BH Lee","year":"2015","unstructured":"Lee, B. H. et al. Modulation of Huh7.5 Spheroid Formation and Functionality Using Modified PEG-Based Hydrogels of Different Stiffness. PLOS ONE 10, e0118123 (2015).","journal-title":"PLOS ONE"},{"key":"35010_CR58","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1099\/vir.0.055772-0","volume":"95","author":"S Liu","year":"2014","unstructured":"Liu, S., Chen, R. & Hagedorn, C. H. Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures. The Journal of General Virology 95, 423\u2013433 (2014).","journal-title":"The Journal of General Virology"},{"key":"35010_CR59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/0255-0857.167330","volume":"33","author":"AR Rajalakshmy","year":"2015","unstructured":"Rajalakshmy, A. R., Malathi, J., Madhavan, H. N. & Samuel, J. K. A. Mebiolgel, a thermoreversible polymer as a scaffold for three dimensional culture of Huh7 cell line with improved hepatocyte differentiation marker expression and HCV replication. Indian Journal of Medical Microbiology 33, 554\u2013559 (2015).","journal-title":"Indian Journal of Medical Microbiology"},{"key":"35010_CR60","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","volume":"20","author":"NJ Barrows","year":"2016","unstructured":"Barrows, N. J. et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell host & microbe 20, 259\u2013270 (2016).","journal-title":"Cell host & microbe"},{"key":"35010_CR61","doi-asserted-by":"publisher","first-page":"e2471","DOI":"10.1371\/journal.pntd.0002471","volume":"7","author":"DJM Cruz","year":"2013","unstructured":"Cruz, D. J. M. et al. Identification of Novel Compounds Inhibiting Chikungunya Virus-Induced Cell Death by High Throughput Screening of a Kinase Inhibitor Library. PLoS Neglected Tropical Diseases 7, e2471 (2013).","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"35010_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2014.09.007","volume":"111","author":"YY Cheung","year":"2014","unstructured":"Cheung, Y. Y., Chen, K. C., Chen, H., Seng, E. K. & Chu, J. J. H. Antiviral activity of lanatoside C against dengue virus infection. Antiviral Research 111, 93\u201399 (2014).","journal-title":"Antiviral Research"},{"key":"35010_CR63","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1128\/AAC.00189-09","volume":"53","author":"M Qing","year":"2009","unstructured":"Qing, M. et al. Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein. Antimicrobial Agents and Chemotherapy 53, 3226\u20133235 (2009).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"35010_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v10040184","volume":"10","author":"J Haviernik","year":"2018","unstructured":"Haviernik, J. et al. Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses 10, 184 (2018).","journal-title":"Viruses"},{"key":"35010_CR65","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","volume":"133","author":"JM Gottwein","year":"2007","unstructured":"Gottwein, J. M. et al. Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a\/2a (S52\/JFH1) Viruses. Gastroenterology 133, 1614\u20131626 (2007).","journal-title":"Gastroenterology"},{"key":"35010_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/hep.22673","volume":"49","author":"JM Gottwein","year":"2009","unstructured":"Gottwein, J. M. et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364\u2013377 (2009).","journal-title":"Hepatology"},{"key":"35010_CR67","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1128\/JVI.02667-09","volume":"84","author":"JM Gottwein","year":"2010","unstructured":"Gottwein, J. M. et al. Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and In Vivo Pathogenesis Studies. Journal of Virology 84, 5277\u20135293 (2010).","journal-title":"Journal of Virology"},{"key":"35010_CR68","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/JVI.01594-10","volume":"85","author":"J Prentoe","year":"2011","unstructured":"Prentoe, J. et al. Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization. Journal of Virology 85, 2224\u20132234 (2011).","journal-title":"Journal of Virology"},{"key":"35010_CR69","doi-asserted-by":"publisher","first-page":"e0140912","DOI":"10.1371\/journal.pone.0140912","volume":"10","author":"U Fahn\u00f8e","year":"2015","unstructured":"Fahn\u00f8e, U. et al. Creation of Functional Viruses from Non-Functional cDNA Clones Obtained from an RNA Virus Population by the Use of Ancestral Reconstruction. PLoS ONE 10, e0140912 (2015).","journal-title":"PLoS ONE"},{"key":"35010_CR70","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1099\/jgv.0.001095","volume":"99","author":"N Mejer","year":"2018","unstructured":"Mejer, N. et al. Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a. Journal of General Virology 99, 1066\u20131077 (2018).","journal-title":"Journal of General Virology"},{"key":"35010_CR71","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","volume":"141","author":"JM Gottwein","year":"2011","unstructured":"Gottwein, J. M., Scheel, T. K. H., Jensen, T. B., Ghanem, L. & Bukh, J. Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3\/4A Protease Recombinant Viruses. Gastroenterology 141, 1067\u20131079 (2011).","journal-title":"Gastroenterology"},{"key":"35010_CR72","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/hep.24692","volume":"55","author":"P Meuleman","year":"2012","unstructured":"Meuleman, P. et al. A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55, 364\u2013372 (2012).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35010-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T14:58:50Z","timestamp":1694098730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35010-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35010"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35010-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17505"}}